Headquarters: Ness Ziona, Israel
Investor Relations: Irina Koffler / +1 917 734 7387 / firstname.lastname@example.org
Sol-Gel is a dermatology company focused on commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.
Exchange / Symbol